Clopidogrel drug interactions: a review of the evidence and clinical implications

References

• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016 Sept 6;134(10):e123–55.
   Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213–260.
   Google Scholar
• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018 Dec 11;72(23Pt A):2915–2931.
   Google Scholar
• Moon JY, Franchi F, Rollini F, et al. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. Prog Cardiovasc Dis. 2018 Jan - Feb;60(4–5):478–490.
   Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015 Jan;12(1):30–47.
   Google Scholar
• Dayoub EJ, Seigerman M, Tuteja S, et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern Med. 2018 July 1;178(7):943–950.
   Google Scholar
• Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010 Nov 16;56(21):1683–1692.
   Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol. 2011 Mar;57(11):1251–1263.
   Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521–1537.
   Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363–375.
   Google Scholar
• Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486–501.
   Google Scholar
• Marín F, González-Conejero R, Capranzano P, et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009 Sept 15;54(12):1041–1057.
   Google Scholar
• Zhu HJ, Wang X, Gawronski BE, et al. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013 Mar;344(3):665–672.
   Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007 Apr 10;49(14):1505–1516.
   Google Scholar
• Baqi Y, Muller CE. Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. Drug Discov Today. 2019 Jan;24(1):325–333.
   Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan;38(1):92–99.
   Google Scholar
• Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011 Jan;17(1):110–116.
   Google Scholar
• Frelinger AL 3rd, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26;61(8):872–879.
   Google Scholar
• Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011 July;32(13):1605–1613.
   Google Scholar
• Tresukosol D, Suktitipat B, Hunnangkul S, et al. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One. 2014;9(10):e110188.
   Google Scholar
• Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020 Mar 9;13(5):606–617.
   Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354–362.
   Google Scholar
• Moon JY, Franchi F, Rollini F, et al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol. 2018 Feb;11(2):151–164.
   Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama. 2009 Aug 26;302(8):849–857.
   Google Scholar
• Klein MD, Williams AK, Lee CR, et al. Clinical utility of CYP2C19 genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):647–652.
   Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Jama. 2010 Oct 27;304(16):1821–1830.
   Google Scholar
• Tarkiainen EK, Holmberg MT, Tornio A, et al. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther. 2015 June;97(6):650–658.
   Google Scholar
• Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–2754.
   Google Scholar
• Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):175–189.
   Google Scholar
• Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65–74.
   Google Scholar
• Funck-Brentano C, Szymezak J, Steichen O, et al. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis. 2013 Dec;106(12):661–671.
   Google Scholar
• Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 3;59(14):1304–1311.
   Google Scholar
• Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol. 2008 Jan 22;51(3):256–260.
   Google Scholar
• Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv. 2010 Oct;3(5):436–441.
   Google Scholar
• Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy. 2010 Aug;30(8):787–796.
   Google Scholar
• van Boxel OS, van Oijen MG, Hagenaars MP, et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010 Nov;105(11):2430–6; quiz 2437.
   Google Scholar
• Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) registry. Circulation. 2011 Feb 8;123(5):474–482.
   Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sept 19;374(9694):989–997.
   Google Scholar
• Goodman SG, Clare R, Pieper KS, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28;125(8):978–986.
   Google Scholar
• Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11;363(20):1909–1917.
   Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(6):411–426.
   Google Scholar
• Abelo A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Aug;28(8):966–972.
   Google Scholar
• Fernando H, Bassler N, Habersberger J, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost. 2011 Aug;9(8):1582–1589.
   Google Scholar
• Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008 Apr;48(4):475–484.
   Google Scholar
• Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010 Mar 16;152(6):337–345.
   Google Scholar
• Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010 Sept 21;153(6):378–386.
   Google Scholar
• Skrzydlo-Radomanska B, Radwan P. Dexlansoprazole – a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191–196.
   Google Scholar
• Ferreiro JL, Ueno M, Tomasello SD, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011 June;4(3):273–279.
   Google Scholar
• Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. 1. N Engl J Med. 1990 Dec 13;323(24):1672–1680.
   Google Scholar
• Rendic S. Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic. Croat Med J. 1999 Sept;40(3):357–367.
   Google Scholar
• Sheng-Wen Wang S, Tsai SS, Hsu PC, et al. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol. 2009 Dec;104(12):3116–3117.
   Google Scholar
• Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008 Aug;24(8):2251–2257.
   Google Scholar
• Ohbuchi M, Noguchi K, Kawamura A, et al. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica. 2012 July;42(7):633–640.
   Google Scholar
• Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on expert consensus documents. Circulation. 2010 Dec 14;122(24):2619–2633.
   Google Scholar
• Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435–1447.
   Google Scholar
• Floyd JS, Kaspera R, Marciante KD, et al. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther. 2012 May;91(5):896–904.
   Google Scholar
• Elsby R, Martin P, Surry D, et al. Solitary Inhibition of the breast cancer resistance protein efflux transporter results in a clinically significant drug-drug interaction with rosuvastatin by causing up to a 2-fold increase in statin exposure. Drug Metab Dispos. 2016 Mar;44(3):398–408.
   Google Scholar
• Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993 Mar;24(3):195–202.
   Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157–181.
   Google Scholar
• Zahno A, Brecht K, Bodmer M, et al. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol. 2010 Sept;161(2):393–404.
   Google Scholar
• Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest. 2005 Aug;35(8):476–481.
   Google Scholar
• Malmstrom RE, Ostergren J, Jorgensen L, et al. Influence of statin treatment on platelet inhibition by clopidogrel – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Intern Med. 2009 Nov;266(5):457–466.
   Google Scholar
• Trenk D, Hochholzer W, Frundi D, et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost. 2008 Jan;99(1):174–181.
   Google Scholar
• Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007 July 24;50(4):291–295.
   Google Scholar
• Itkonen MK, Tornio A, Neuvonen M, et al. Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. Drug Metab Dispos. 2015 Nov;43(11):1655–1660.
   Google Scholar
• Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003 Jan 7;107(1):32–37.
   Google Scholar
• Park Y, Jeong YH, Tantry US, et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur Heart J. 2012 Sept;33(17):2151–2162.
   Google Scholar
• Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy – the PEARL randomized cross-over study. Eur J Pharmacol. 2014 Feb;15(725):18–22.
   Google Scholar
• Brophy JM, Babapulle MN, Costa V, et al. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am Heart J. 2006 Aug;152(2):263–269.
   Google Scholar
• Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003 Nov;25(11):2822–2835.
   Google Scholar
• Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: myth or reality? J Am Coll Cardiol. 2007 July 24;50(4):296–298.
   Google Scholar
• Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol. 2003 Aug 1;92(3):285–288.
   Google Scholar
• Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343–370.
   Google Scholar
• Kim SJ, Yoshikado T, Ieiri I, et al. Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab Dispos. 2016 Oct;44(10):1622–1632.
   Google Scholar
• Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Circ J. 2014;78(3):679–684.
   Google Scholar
• Tornio A, Neuvonen PJ, Niemi M, et al. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):83–95.
   Google Scholar
• Prueksaritanont T, Richards KM, Qiu Y, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res. 2005 Jan;22(1):71–78.
   Google Scholar
• Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–427.
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722.
   Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489–1499.
   Google Scholar
• Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018 July;57(7):769–779.
   Google Scholar
• Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014 Dec;32(6):297–301.
   Google Scholar
• Katoh M, Nakajima M, Shimada N, et al. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11–12):843–852.
   Google Scholar
• Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008 Nov 4;52(19):1557–1563.
   Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1895–1900.
   Google Scholar
• Park JJ, Park KW, Kang J, et al. CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel. Circ J. 2013;77(5):1289–1296.
   Google Scholar
• Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost. 2010 May;103(5):920–925.
   Google Scholar
• Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 Dec;29(6):687–710.
   Google Scholar
• Harmsze AM, van Werkum JW, Souverein PC, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost. 2011 Oct;9(10):1892–1901.
   Google Scholar
• Schmidt M, Johansen MB, Robertson DJ, et al. Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events. Eur J Clin Invest. 2012 Mar;42(3):266–274.
   Google Scholar
• Good CW, Steinhubl SR, Brennan DM, et al. Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the clopidogrel for the reduction of events during observation (CREDO) trial. Circ Cardiovasc Interv. 2012 Feb 1;5(1):77–81.
   Google Scholar
• Olesen JB, Gislason GH, Charlot MG, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol. 2011 Jan 25;57(4):409–417.
   Google Scholar
• Gladding P, Webster M, Zeng I, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008 Dec;1(6):612–619.
   Google Scholar
• Angiolillo DJ, Jakubowski JA, Ferreiro JL, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014 Sept 9;64(10):1005–1014.
   Google Scholar
• Harmsze AM, Van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets. 2011;22(2):98–102.
   Google Scholar
• Itkonen MK, Tornio A, Neuvonen M, et al. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab Dispos. 2016 Aug;44(8):1364–1371.
   Google Scholar
• Wei Y, Lin FJ, Lin SY, et al. Risk of hypoglycemia and concomitant use of repaglinide and clopidogrel: a population-based nested case-control study. Clin Pharmacol Ther. 2019 Dec;106(6):1346–1352.
   Google Scholar
• Tornio A, Niemi M, Neuvonen PJ, et al. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci. 2012 June;33(6):312–322.
   Google Scholar
• Shao H, Lu J, Xu YT, et al. Metabolic interaction potential between clopidogrel and sulfonylurea antidiabetic agents: effects on clopidogrel bioactivation. Pharmacology. 2016;97(1–2):18–24.
   Google Scholar
• Tornio A, Filppula AM, Kailari O, et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther. 2014 Oct;96(4):498–507.
   Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003 Dec 9;108(23):2941–2948.
   Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 May;36(5):1384–1395.
   Google Scholar
• Shebley M, Liu J, Kavetskaia O, et al. Mechanisms and predictions of drug-drug interactions of the hepatitis C virus three direct-acting antiviral regimen: paritaprevir/ritonavir, ombitasvir, and dasabuvir. Drug Metab Dispos. 2017 July;45(7):755–764.
   Google Scholar
• Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014 June;48(6):734–740.
   Google Scholar
• Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. Aids. 2003 May 23;17(8):1179–1193.
   Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Apr 15;75:2950–2973.
   Google Scholar
• Shebley M, Fu W, Badri P, et al. Physiologically based pharmacokinetic modeling suggests limited drug-drug interaction between clopidogrel and dasabuvir. Clin Pharmacol Ther. 2017 Oct;102(4):679–687.
   Google Scholar
• Itkonen MK, Tornio A, Lapatto-Reiniluoto O, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019 01;105(1):219–228.
   Google Scholar
• Hurst M, Faulds D. Lopinavir. Drugs. 2000 Dec;60(6):1371–9; discussion 1380–1.
   Google Scholar
• Rathbun RC, Liedtke MD. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics. 2011 Oct 21;3(4):745–781.
   Google Scholar
• Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. Aids. 2005 Jan 28;19(2):145–152.
   Google Scholar
• Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother. 2007 Apr;8(6):851–871.
   Google Scholar
• Xu C, Desta Z. In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet. 2013;28(4):362–371.
   Google Scholar
• Abdelhady AM, Desta Z, Jiang F, et al. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. J Clin Pharmacol. 2014 Jan;54(1):87–96.
   Google Scholar
• Jiang F, Desta Z, Shon JH, et al. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol. 2013 Jan;75(1):244–253.
   Google Scholar
• Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017 Mar 6;7:43395.
   Google Scholar
• Baneyx G, Parrott N, Meille C, et al. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration. Eur J Pharm Sci. 2014 June 2;56:1–15.
   Google Scholar
• Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost. 2010 Aug;8(8):1820–1827.
   Google Scholar
• Lebel M. Pharmacokinetic properties of clarithromycin: a comparison with erythromycin and azithromycin. Can J Infect Dis. 1993 May;4(3):148–152.
   Google Scholar
• Kim KA, Park JY, Lee JS, et al. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631–637.
   Google Scholar
• Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med. 2001 Sept;19(5):420–424.
   Google Scholar
• Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Dec;45(6):737–779.
   Google Scholar
• Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735–741.
   Google Scholar
• Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006 June;174(12):1715–1722.
   Google Scholar
• Chen XP, Tan ZR, Huang SL, et al. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264–271.
   Google Scholar
• Jaichander P, Selvarajan K, Garelnabi M, et al. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142–2148.
   Google Scholar
• Oh J, Shin D, Lim KS, et al. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Clin Pharmacol Ther. 2014 June;95(6):608–616.
   Google Scholar
• Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 2000 June 20;101(24):2823–2828.
   Google Scholar
• Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009 Oct;7(10):1195–1201.
   Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017 Nov 14;136(20):1955–1975.
   Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 4;368(14):1303–1313.
   Google Scholar
• Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012 July;34(1):44–55.
   Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. Jama. 2012 Jan 18;307(3):265–274.
   Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121(4):527–534.
   Google Scholar
• Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation. J Interv Cardiol. 2015 Oct;28(5):415–419.
   Google Scholar
• Judge HM, Buckland RJ, Jakubowski JA, et al. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets. 2016;27(3):191–195.
   Google Scholar
• Franchi F, Rollini F, Muñiz-Lozano A, et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013 Oct;11(10):1279–1291.
   Google Scholar
• Angiolillo DJ, Curzen N, Gurbel P, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J Am Coll Cardiol. 2014 Apr 22;63(15):1500–1509.
   Google Scholar
• Franchi F, Rollini F, Rivas Rios J, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. Circulation. 2018 June 5;137(23):2450–2462.
   Google Scholar
• Thomsen R, Rasmussen HB, Linnet K. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos. 2014 Jan;42(1):126–133.
   Google Scholar
• Kristensen KE, Zhu HJ, Wang X, et al. Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. Clin Pharmacol Ther. 2014 Dec;96(6):713–722.
   Google Scholar
• Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013 Jan;23(1):1–8.
   Google Scholar
• Agergaard K, Mau-Sørensen M, Stage TB, et al. Clopidogrel-paclitaxel drug-drug interaction: a pharmacoepidemiologic study. Clin Pharmacol Ther. 2017 Sept;102(3):547–553.
   Google Scholar
• Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994 Nov 1;54(21):5543–5546.
   Google Scholar
• Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005 Sept-Oct;46(5):464–494.
   Google Scholar
• Delavenne X, Magnin M, Basset T, et al. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundam Clin Pharmacol. 2013 Dec;27(6):683–689.
   Google Scholar
• Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007 Aug 21;120(2):188–192.
   Google Scholar
• Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet. 1993 June;24(6):472–495.
   Google Scholar
• Lee JH, Shin YJ, Oh JH, et al. Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs. Arch Pharm Res. 2012 Oct;35(10):1831–1837.
   Google Scholar
• Sibbing D, von Beckerath N, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J. 2010 May;31(10):1205–1211.
   Google Scholar
• Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227–1246.
   Google Scholar
• Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med. 2008 Nov;264(5):472–480.
   Google Scholar
• Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm. 1999 Jan 15;56(2):125–38; quiz 139–41.
   Google Scholar
• Roby CA, Anderson GD, Kantor E, et al. St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther. 2000 May;67(5):451–457.
   Google Scholar
• Trana C, Toth G, Wijns W, et al. St. John’s Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John’s Trial). J Cardiovasc Transl Res. 2013 June;6(3):411–414.
   Google Scholar
• Lau WC, Welch TD, Shields T, et al. The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011 Jan;57(1):86–93.
   Google Scholar
• Murdoch D, Goa KL, Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs. 2003;63(19):2051–2077.
   Google Scholar
• Kazmi F, Barbara JE, Yerino P, et al. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos. 2015 Apr;43(4):523–533.
   Google Scholar
• Itkonen MK, Tornio A, Neuvonen M, et al. Clopidogrel and gemfibrozil strongly inhibit the CYP2C8-dependent formation of 3-hydroxydesloratadine and increase desloratadine exposure in humans. Drug Metab Dispos. 2019 Apr;47(4):377–385.
   Google Scholar
• Lipworth BJ. Leukotriene-receptor antagonists. Lancet. 1999 Jan 2;353(9146):57–62.
   Google Scholar
• Itkonen MK, Tornio A, Filppula AM, et al. Clopidogrel but not prasugrel significantly inhibits the CYP2C8-mediated metabolism of montelukast in humans. Clin Pharmacol Ther. 2018 Sept;104(3):495–504.
   Google Scholar
• Karonen T, Neuvonen PJ, Backman JT. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol. 2012 Feb;73(2):257–267.
   Google Scholar
• Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159–166.
   Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000 Oct;28(10):1222–1230.
   Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005 June;77(6):553–559.
   Google Scholar
• Tassaneeyakul W, Guo LQ, Fukuda K, et al. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys. 2000 June 15;378(2):356–363.
   Google Scholar
• Holmberg MT, Tornio A, Neuvonen M, et al. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol Ther. 2014 Mar;95(3):307–313.
   Google Scholar